Back to Search Start Over

Affimer proteins are versatile and renewable affinity reagents

Authors :
Michael E. Webb
Alastair D. Smith
Gina A. Smith
Mark J. Drinkhill
Sophie J Heseltine
Margaret A. Knowles
Filomena Esteves
Joanne E. Nettleship
Sandra M. Bell
Michael A. Harrison
Raj Prasad
Vikesh Patel
Alexander Balls
Paul Ko Ferrigno
Danah AlQallaf
Ruth E. Hughes
Christian Tiede
Louise Coletta
Hannah F. Kyle
Anna A Tang
Matthew Johnson
Ashley P.E. Roberts
Imeshi Wijetunga
Raymond J. Owens
Alistair Curd
Jonathan D. Lippiat
Laura C. Zanetti-Domingues
Geoffrey W. Platt
Darren C. Tomlinson
Rebecca L. Ross
Sarah A. Goodchild
Naomi Gibson
Nicola Ingram
Robert Bedford
Michael J. McPherson
Sreenivasan Ponnambalam
Thomas Taylor
Marisa L. Martin-Fernandez
Iain W. Manfield
Sarah R. Needham
Yashar Sadigh
Azhar Maqbool
Thomas P. Peacock
Michelle Peckham
Heather L. Martin
Robin S. Bon
Source :
eLife, Vol 6 (2017), eLife
Publication Year :
2017
Publisher :
eLife Sciences, 2017.

Abstract

Molecular recognition reagents are key tools for understanding biological processes and are used universally by scientists to study protein expression, localisation and interactions. Antibodies remain the most widely used of such reagents and many show excellent performance, although some are poorly characterised or have stability or batch variability issues, supporting the use of alternative binding proteins as complementary reagents for many applications. Here we report on the use of Affimer proteins as research reagents. We selected 12 diverse molecular targets for Affimer selection to exemplify their use in common molecular and cellular applications including the (a) selection against various target molecules; (b) modulation of protein function in vitro and in vivo; (c) labelling of tumour antigens in mouse models; and (d) use in affinity fluorescence and super-resolution microscopy. This work shows that Affimer proteins, as is the case for other alternative binding scaffolds, represent complementary affinity reagents to antibodies for various molecular and cell biology applications. DOI: http://dx.doi.org/10.7554/eLife.24903.001<br />eLife digest Many of the molecules that are essential for life are too small to be visible inside cells. So, scientists use large complex proteins called antibodies that bind to these molecules to detect whether they are present and show where they are in a cell. As well as being useful tools in experiments, these antibodies can be used to help identify and treat diseases. The body produces antibodies in response to an infection. The antibodies used in experiments are purified from animal blood, but this method of producing antibodies has flaws. For example, it can be difficult to make identical batches of antibody that always behave in the same way. So scientists have developed “alternative binding proteins” that can be made in the laboratory. These proteins are much less complicated and can be developed more quickly than antibodies, and can easily be adapted for a variety of uses. An alternative binding protein called an Affimer behaves in a similar way to an antibody by binding tightly to its target molecule, but is much more stable to acidity and high temperature. Tiede et al. have now tested how well the Affimer works in a wide range of different experiments that normally use antibodies to analyse the amount of a particular molecule inside a cell. The results of the tests show that the Affimer behaves in the same way as antibodies, and sometimes works more effectively. Tiede et al. show that an Affimer can help to reveal how a particular molecule works within a cell, to create detailed pictures of molecules in cells and tissues, and to identify a tumour. It can also be used alongside a new technique called ‘super-resolution microscopy’ that allows researchers to watch the activity of individual molecules. Future challenges are to test the Affimer in even more applications and to encourage its wider use by researchers, alongside other alternative binding proteins, as as replacements for some antibodies. This could ultimately lead to the development of faster and more efficient diagnostic, imaging and therapeutic tests. DOI: http://dx.doi.org/10.7554/eLife.24903.002

Details

Language :
English
ISSN :
2050084X
Database :
OpenAIRE
Journal :
eLife, Vol 6 (2017), eLife
Accession number :
edsair.doi.dedup.....a266f4782feecdb6c1e445111cec72b0